Status and phase
Conditions
Treatments
About
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
To be eligible for inclusion in the primary escalation and expansion cohort 1 in this study, patients must meet all of the following criteria:
Age 18 years or older
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):
Exclusion criteria
Patients who meet any of the following criteria are not eligible for the primary escalation and expansion cohorts of this study:
Current or past transformation of CLL/SLL to prolymphocytic leukemia (PLL), non-Hodgkin lymphoma, or Hodgkin lymphoma aggressive lymphoma outlined in the inclusion criteria for the optional cohort.
Active and uncontrolled autoimmune cytopenia(s)
Any of the following prior therapies within 14 days prior to cycle 1, day 1:
Primary purpose
Allocation
Interventional model
Masking
63 participants in 8 patient groups
Loading...
Central trial contact
Kai Zhang; Gerald Messerschmidt, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal